StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy] by Quarter

Trajenta (linagliptin) — U.S. revenue ($M) [legacy] ($M)

Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy]: $31.1M in Q4 2020, down 41.2% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2020
31.1
Period ended Dec 31, 2020
Change on a year earlier
-41.2%
52.9 in Q4 2019
History
16 quarters
Since Q1 2017
Sources
12
Documents cited below

Where the Q4 2020 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2022-02-23) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTrajenta (linagliptin) — U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2020Dec 31, 202031.1-41.2%Form 10-K (filed 2022-02-23) ↗
Q3 2020Sep 30, 202019.4-67.7%Form 10-Q (filed 2020-10-28) ↗
Q2 2020Jun 30, 202016.4-74.6%Form 10-Q (filed 2020-07-31) ↗
Q1 2020Mar 31, 202028.7-39.5%Form 10-Q (filed 2020-05-01) ↗
Q4 2019Dec 31, 201952.9-15.9%Form 10-K (filed 2022-02-23) ↗
Q3 2019Sep 30, 201960.1+19.5%Form 10-Q (filed 2020-10-28) ↗
Q2 2019Jun 30, 201964.5+13.6%Form 10-Q (filed 2020-07-31) ↗
Q1 2019Mar 31, 201947.4-12.4%Form 10-Q (filed 2020-05-01) ↗
Q4 2018Dec 31, 201862.9+61.3%Form 10-K (filed 2021-02-17) ↗
Q3 2018Sep 30, 201850.3-26.5%Form 10-Q (filed 2019-10-25) ↗
Q2 2018Jun 30, 201856.8-6.0%Form 10-Q (filed 2019-08-02) ↗
Q1 2018Mar 31, 201854.1+19.2%Form 10-Q (filed 2019-05-02) ↗
Q4 2017Dec 31, 201739–Form 10-K (filed 2020-02-19) ↗
Q3 2017Sep 30, 201768.4–Form 10-Q (filed 2018-11-06) ↗
Q2 2017Jun 30, 201760.4–Form 10-Q (filed 2018-07-25) ↗
Q1 2017Mar 31, 201745.4–Form 10-Q (filed 2018-04-27) ↗

Cite this data

StockData. (2026). Eli Lilly Trajenta (linagliptin) — U.S. revenue [legacy] ($M), quarterly Q1 2017–Q4 2020 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-trajenta-us

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.